Recursion Pharmaceuticals, Inc.
Financials
Valuation Metrics
Recursion Pharmaceuticals, Inc.'s Market Cap is $1.88B. At end of 2025 it was $2.15B. Ranked #2072 of 3,121 in US market (top 66%), #805 of 1,463 on NASDAQ (top 55%), #145 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.88B | US#2,072/3,121 Sec#145/266 |
| Revenue | $55M | US#2,763/3,121 Sec#143/266 |
| Net Income | $-519M | US—/3,121 Sec—/266 |
| Total Assets | $1.21B | US#2,391/3,121 Sec#88/266 |
| Net Assets | $915M | US#1,822/3,121 Sec#72/266 |
| Employees | 600 | US#2,199/3,121 Sec#75/266 |
| Value | ||
| P/B | 2.05x | US#1,284/3,121 Sec#53/266 |
| P/S | 34.25x | US#2,891/3,121 Sec#155/266 |
| FCF Yield | -18.85% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -56.71% | US#2,707/3,121 Sec#166/266 |
| ROA | -42.79% | US#2,958/3,121 Sec#195/266 |
| Op. Margin | -991.72% | US#2,830/3,121 Sec#167/266 |
| Revenue Growth | -14.88% | US#2,656/3,121 Sec#149/266 |
| Financial Health | ||
| Debt Ratio | 32.53% | US#368/3,121 Sec#112/266 |
| Total Debt | $62M | US#2,565/3,121 Sec#144/266 |
| FCF | $-354M | US#2,870/3,121 Sec#242/266 |
| Cash | $546M | US#1,022/3,121 Sec#53/266 |
| Current Ratio | 5.03x | US#470/3,121 Sec#146/266 |
| Performance | ||
| 1Y Return | -24.84% | US#2,520/3,121 Sec#217/266 |
| 1M Return | 14.56% | US#148/3,121 Sec#19/266 |
| From 52W High | -50.70% | US#2,742/3,121 Sec#218/266 |
| 1Y MDD | -58.17% | US#2,741/3,121 Sec#211/266 |
| Trading | ||
| Volume | 27,956,413 shares | US#38/3,121 Sec#2/266 |
| Trading Value | $97M | US#839/3,121 Sec#54/266 |
| Per Share | ||
| EPS | $-0.98 | US—/3,121 Sec—/266 |
| BPS | $1.72 | US#2,601/3,121 Sec#185/266 |
Company Info
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.